Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 887 INR 0%
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Divi's Laboratories Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Divi's Laboratories Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Divi's Laboratories Ltd
NSE:DIVISLAB
Other Long-Term Assets
â‚ą680m
CAGR 3-Years
4%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Other Long-Term Assets
â‚ą339.3m
CAGR 3-Years
-46%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Other Long-Term Assets
â‚ą2.1B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Vimta Labs Ltd
NSE:VIMTALABS
Other Long-Term Assets
â‚ą99.7m
CAGR 3-Years
63%
CAGR 5-Years
18%
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Other Long-Term Assets
â‚ą417.2m
CAGR 3-Years
54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. has carved an enviable niche for itself in the global pharmaceutical industry, with its origins tracing back to 1990 in Hyderabad, India. With a steadfast focus on research and development, the company stands as a formidable force in the Active Pharmaceutical Ingredients (APIs) and Intermediates manufacturing sector. Its strategy hinges on two complementary business segments: generic APIs and custom synthesis of APIs and intermediates. By catering to a broad spectrum of therapeutic areas, from cardiovascular ailments to pain management, Divi's capitalizes on economies of scale and technological innovation to produce cost-effective, high-quality pharmaceutical products. This strategy not only aligns with the company’s expertise in process development and chemical synthesis but also positions it as a key supplier to major pharmaceutical companies worldwide, providing a significant portion of their API requirements. The crux of Divi's financial engine lies in its custom synthesis segment, where it forms strategic alliances with global pharmaceutical giants, offering end-to-end solutions from drug discovery to commercialization. This vertical is fueled by long-term contracts that bolster the company’s revenue visibility and profitability. Meanwhile, the generic APIs segment benefits from the rising global demand for affordable healthcare solutions, particularly in emerging markets. Divi’s Laboratories leverages its state-of-the-art manufacturing facilities, which are compliant with international regulatory standards, to ensure efficient production cycles and maintain a consistent supply chain. Through its blend of innovative R&D, a robust manufacturing backbone, and strategic partnerships, Divi's Laboratories adeptly navigates the complexities of the pharmaceutical industry, making it a stalwart in the sector's supply chain ecosystem.

DIVISLAB Intrinsic Value
3 256.64 INR
Overvaluation 45%
Intrinsic Value
Price

See Also

What is Divi's Laboratories Ltd's Other Long-Term Assets?
Other Long-Term Assets
680m INR

Based on the financial report for Jun 30, 2024, Divi's Laboratories Ltd's Other Long-Term Assets amounts to 680m INR.

What is Divi's Laboratories Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
-14%

Over the last year, the Other Long-Term Assets growth was 6%. The average annual Other Long-Term Assets growth rates for Divi's Laboratories Ltd have been 4% over the past three years , -14% over the past five years .

Back to Top